As published in Nature in 2011, piperlongumine also manifests antiangiogenic effects via its ability to reduce vascular endothelial growth factor (VEGF) and CD31 kinases in cancer cells, which in turn inhibits the formation of new blood vesicles for tumor cells, as well as its ability to work as an antimetastatic agent for the cancer cells [11]. This evidence concerns the gene PECAM1 and cancer.